BioTuesdays

Author - Leonard Zehr

oramed
Developments

Oramed Pharma issues letter to shareholders

In a letter to shareholders, Nadav Kidron, CEO of Oramed Pharmaceuticals (NASDAQ:ORMP), detailed the company’s recent achievements and future milestones. “2015 was a very significant year for us at Oramed, setting the...

January 6, 2016
Can-Fite Logo
Developments

Can-Fite submits Phase 3 protocol for RA study

Can-Fite BioPharma (NYSE MKT:CANF; TASE:CFBI) has submitted its Phase 3 clinical study protocol to the Institutional Review Board of Barzilai Medical Center in Israel and will file similar submissions in several...

January 5, 2016
Cynosure
Markets

Stifel ups Cynosure price target to $50

Stifel has raised its price target for Cynosure (NASDAQ:CYNO) to $50 from $44, reflecting revised estimates and an increased sales multiple due to the company’s higher growth rate. The stock closed at $42 on Monday...

January 5, 2016
Feature

BioSight developing non-toxic drug against leukemia

By Len Zehr Closely-held BioSight is in clinical development with its lead chemotherapy drug, Astarabine, as a non-toxic treatment for hematologic malignancies, including acute myeloid leukemia (AML). “Treatment and...

January 5, 2016
oramed
Markets

Oramed closes licensing, investment deal in China

Oramed Pharmaceuticals (NASDAQ:ORMP) has closed a license and investment deal with Hefei Tianhui Incubation of Technologies (HTIT) of China. Oramed has sold 1,155,367 restricted common shares to HTIT at a price of $10...

December 29, 2015
Adamas Pharmaceuticals Logo
Markets

WB ups Adamas Pharma price target to $42

William Blair has raised its price target on Adamas Pharmaceuticals (NASDAQ:ADMS) to $42 from $35 after the company announced positive top-line results from its Phase 3 EASE LID trial with lead candidate ADS-5102...

December 23, 2015
Feature

Season’s Greetings (and JPM 2016)

Wow, what an interesting year 2015 has turned out to be! Everyone at BioTuesdays would like to wish you all a safe and happy holiday season. After taking a short break to spend time with family and friends, we will be...

December 22, 2015
Can-Fite Logo
Developments

Can-Fite gets patent in Japan for CF101

The Japan Patent Office has granted Can-Fite BioPharma (NYSE MKT:CANF) (TASE:CFBI) a patent for its lead drug candidate, CF101, for the reduction of intraocular pressure (IOP). CF101 is an A3 adenosine receptor (A3AR)...

December 17, 2015